New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)Presenters:Christopher R. Flowers, MD, MSDepartment Chair, Department of Lymphoma/MyelomaDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer Center Houston, TexasKami Maddocks, MDProfessor of Clinical Internal MedicineDivision of Internal MedicineDepartment of HematologyThe Ohio State UniversityLymphoma Program DirectorThe Ohio State University James Cancer HospitalColumbus, Ohio

There are no comments yet.

Please log in to write the first comment.